Cargando…

A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine

BACKGROUND: KAF156 is a novel imidazolopiperazine anti-malarial with activity against pre-erythrocytic liver stages, asexual and sexual blood stages. Based on in vitro data, a two-way pharmacokinetic interaction was hypothesized for KAF156 use in combination with piperaquine (PPQ) as both drugs are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leong, F. Joel, Jain, Jay Prakash, Feng, Yiyan, Goswami, Budhaditya, Stein, Daniel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756412/ https://www.ncbi.nlm.nih.gov/pubmed/29304859 http://dx.doi.org/10.1186/s12936-017-2162-8

Ejemplares similares

A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 and piperaquine (PPQ)
por: Stein, Daniel S, et al.
Publicado: (2014)

KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission
por: Kuhen, Kelli L., et al.
Publicado: (2014)

A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
por: Leong, F. Joel, et al.
Publicado: (2014)

Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand
por: Tarning, J, et al.
Publicado: (2014)

Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria
por: Wattanakul, Thanaporn, et al.
Publicado: (2021)

Pharmacokinetics‐Pharmacodynamics of High‐Dose Ivermectin with Dihydroartemisinin‐Piperaquine on Mosquitocidal Activity and QT‐Prolongation (IVERMAL)
por: Smit, Menno R., et al.
Publicado: (2018)

Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development
por: Zaloumis, Sophie, et al.
Publicado: (2012)

Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers
por: Chotsiri, Palang, et al.
Publicado: (2017)

Pharmacokinetics of Piperaquine in Pregnant Women in Sudan with Uncomplicated Plasmodium falciparum Malaria
por: Adam, Ishag, et al.
Publicado: (2012)

Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy
por: Chotsiri, Palang, et al.
Publicado: (2021)

Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents
por: Luo, Wanhe, et al.
Publicado: (2019)

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling
por: Hodel, Eva Maria, et al.
Publicado: (2014)

Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults
por: Banda, Clifford G., et al.
Publicado: (2018)

Population Pharmacokinetic Assessment of the Effect of Food on Piperaquine Bioavailability in Patients with Uncomplicated Malaria
por: Tarning, Joel, et al.
Publicado: (2014)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
por: Minzi, Omary Mashiku, et al.
Publicado: (2021)

Pharmacokinetic-pharmacodynamic correlations in the development of ginger extract as an anticancer agent
por: Mukkavilli, Rao, et al.
Publicado: (2018)

A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria
por: Cherkaoui‐Rbati, Mohammed H., et al.
Publicado: (2022)

Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis
por: Hoglund, Richard M., et al.
Publicado: (2017)

Stability profiling of anti-malarial drug piperaquine phosphate and impurities by HPLC-UV, TOF-MS, ESI-MS and NMR
por: Yan, Fang, et al.
Publicado: (2014)

Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
por: Hanboonkunupakarn, Borimas, et al.
Publicado: (2014)

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
por: Staehli Hodel, Eva Maria, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents
por: Rizk, M. L., et al.
Publicado: (2019)

A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies
por: Ahn, Jae Eun, et al.
Publicado: (2023)

Towards optimal design of anti-malarial pharmacokinetic studies
por: Simpson, Julie A, et al.
Publicado: (2009)

Reproductive and endocrine effects of artemisinin, piperaquine, and artemisinin-piperaquine combination in rats
por: Li, Xiaobo, et al.
Publicado: (2022)

Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine
por: Zongo, Issaka, et al.
Publicado: (2014)

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects
por: Green, Justin A., et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
por: Akizawa, Tadao, et al.
Publicado: (2018)

A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan
por: Hoglund, Richard M, et al.
Publicado: (2012)

Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literature
por: Kahyaoğlu, Serkan, et al.
Publicado: (2017)

Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.
por: Newell, D. R.
Publicado: (1990)

Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study
por: Ewing, Victoria L, et al.
Publicado: (2015)

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria
por: Darpo, Borje, et al.
Publicado: (2015)

Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018
por: Gansané, Adama, et al.
Publicado: (2021)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eg1na52enivgk2nbgti2ioe70j